Trial Profile
A Phase II, Multicentre, Randomised, Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Intravenous Infusions of AZD9773 (CytoFab™) in Japanese Patients With Severe Sepsis and/or Septic Shock
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Anti-TNF-alpha polyclonal antibody (Primary)
- Indications Sepsis; Septic shock
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AstraZeneca
- 06 Jun 2014 New trial record